Avanir Could Drop Zenvia Following “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will meet with FDA to discuss additional safety and efficacy requirements.
You may also be interested in...
Avanir Divests FazaClo To Azur Pharma To Fund Zenvia Studies
Azur Pharma will pay $42 million up front to acquire the schizophrenia medication and commercial infrastructure.
Avanir Divests FazaClo To Azur Pharma To Fund Zenvia Studies
Azur Pharma will pay $42 million up front to acquire the schizophrenia medication and commercial infrastructure.
Avanir Restructures After Ending Deals With Novartis, AstraZeneca
Plan to reduce operating expenses by $20 million will include some headcount reductions, CEO Katkin tells “The Pink Sheet” DAILY